Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2009-02-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1073/pnas.0813175106PMID 19202079PMCID PMC2650334
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pillars Article: Control of Regulatory T Cell Development by the Transcription Factor Foxp3. Science 2003. 299: 1057-1061.

  2017cited by this paper
• Pillars article: CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405-413.

  2011cited by this paper
• NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells

  2009cited by this paper
• Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells

  2008cited by this paper
• FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions.

  2008cited by this paper
• CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

  2008cited by this paper
• Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

  2008influential reference
• CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

  2008cited by this paper
• Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy.

  2008cited by this paper
• The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.

  2008cited by this paper
• A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer

  2007cited by this paper
• CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma

  2007cited by this paper
• Interferons, immunity and cancer immunoediting

  2006cited by this paper
• CD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients1

  2006cited by this paper
• CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

  2006cited by this paper
• Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

  2005cited by this paper
• Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.

  2005cited by this paper
• Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

  2005cited by this paper
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

  2004cited by this paper
• Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

  2003cited by this paper
• Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

  2003cited by this paper
• Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.

  2003cited by this paper
• Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1

  2002cited by this paper
• Supporting Online Material

  2002cited by this paper
• Decision making in the immune system: The lineage decisions of helper T cells

  2002cited by this paper
• Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues

  2001cited by this paper
• ICOS co-stimulatory receptor is essential for T-cell activation and function

  2001cited by this paper
• The CD28-related molecule ICOS is required for effective T cell-dependent immune responses.

  2000cited by this paper
• A novel transcription factor, T-bet, directs Th1 lineage commitment.

  2000cited by this paper
• T-cell co-stimulation through B7RP-1 and ICOS

  1999cited by this paper
• Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

  1999cited by this paper
• ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28

  1999cited by this paper
• ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28

  1999cited by this paper
• The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells.

  1997cited by this paper
• CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

  1996cited by this paper
• Enhancement of Antitumor Immunity by CTLA-4 Blockade

  1996cited by this paper
• CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

  1995cited by this paper
• CTLA-4 can function as a negative regulator of T cell activation.

  1994cited by this paper

• CTLA-4: a promising immunosuppressive immune checkpoint in prostate cancer therapy.

  2026cites this paper
• ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation

  2026cites this paper
• Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade

  2025cites this paper
• Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefit.

  2025cites this paper
• PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes.

  2025cites this paper
• Gut microbiota reshaping the pancreatic cancer immune microenvironment: new avenues for immunotherapy

  2025cites this paper
• Gut microbiota reshapes the TNBC immune microenvironment: Emerging immunotherapeutic strategies.

  2025cites this paper
• Immune Modulation During Treatment with Enzalutamide Alone or with Radium-223 in Patients with Castration Resistant Prostate Cancer

  2025cites this paper
• Prostate cancer immunotherapy-based strategies: an updated review emphasizing immune checkpoint inhibitors

  2025cites this paper
• IFN-γ Approaches in Tumor Suppression, Its Challenges, and Future Directions: A Review of Recent Advances

  2025cites this paper
• Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1

  2025cites this paper
• Bhlhe40 Coordinates T Cell Programs with Distinct CD4 and CD8 T Cell Requirements for Anti-PD-1 Versus Anti-CTLA-4

  2025cites this paper
• Spatial multi-omics and deep learning reveal fingerprints of immunotherapy response and resistance in hepatocellular carcinoma

  2025cites this paper
• ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis

  2025cites this paper
• CTLA-4 therapy and dementia: A review of immunomodulation in neurodegenerative disease.

  2025cites this paper
• ICOS signaling is involved in the development of allergic rhinitis by regulating the differentiation of T cells, especially Th2 cells.

  2025cites this paper
• Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification

  2025cites this paper
• Critical role of the gut microbiota in immune responses and cancer immunotherapy

  2024cites this paper
• Toxicity in the era of immune checkpoint inhibitor therapy

  2024cites this paper
• HMGB3 Contributes to Anti‐PD‐1 Resistance by Inhibiting IFN‐γ‐Driven Ferroptosis in TNBC

  2024cites this paper
• Insight of immune checkpoint inhibitor related myocarditis.

  2024cites this paper
• Peripheral Blood TCRβ Repertoire, IL15, IL2 and Soluble Ligands for NKG2D Activating Receptor Predict Efficacy of Immune Checkpoint Inhibitors in Lung Cancer

  2024cites this paper
• Nature's Arsenal: Harnessing the Capacity of Phytochemicals to Enhance Immune Checkpoint Inhibitor Therapy of Cancers: An Especial Attention to Brain Malignancies.

  2024cites this paper
• Unraveling Th subsets: insights into their role in immune checkpoint inhibitor therapy

  2024cites this paper
• ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis

  2024cites this paper
• Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells.

  2024cites this paper
• Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy

  2024cites this paper
• Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy

  2023cites this paper
• Dual immune checkpoints inhibition: Cancer treatment and immunological modes of action

  2023cites this paper
• Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell– and CXCR3-dependent manner

  2023cites this paper
• Research advances in immune checkpoint drugs for non-small cell lung cancer

  2023cites this paper
• Сytotoxic T lymphocyte-associated protein-4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas.

  2023cites this paper
• CTLA-4 Pathway Is Instrumental in Giant Cell Arteritis

  2023cites this paper
• The Role Ipilimumab Plays in the Treatment of Melanoma

  2023cites this paper
• Regulating the regulatory T cells as cell therapies in autoimmunity and cancer

  2023cites this paper
• Synthesis and Biological Evaluation of Biaryl Alkyl Ethers as Inhibitors of IDO1.

  2023cites this paper
• The Regulatory Effects of MicroRNAs on Tumor Immunity

  2022cites this paper
• The paradox of immune checkpoint inhibition re-activating tuberculosis

  2022cites this paper
• The role of immune checkpoints in cardiovascular disease

  2022cites this paper
• Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer

  2022cites this paper
• Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies

  2022cites this paper
• CD4+ Cytotoxic T Lymphocytes in Cancer Immunity and Immunotherapy

  2022cites this paper
• Elaborating on anti CTLA-4 mechanisms of action using an agent-based modeling approach

  2022cites this paper
• Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy.

  2022cites this paper
• Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets

  2022cites this paper
• Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?

  2022cites this paper
• New cytometry tools for immune monitoring during cancer immunotherapy

  2021cites this paper
• Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer

  2021cites this paper
• Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action

  2021cites this paper
• Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

  2021cites this paper
• Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer

  2021cites this paper
• The Next Decade of Immune Checkpoint Therapy.

  2021cites this paper
• Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients

  2021cites this paper
• Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers

  2021cites this paper
• Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report

  2021cites this paper
• Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes

  2021cites this paper
• Role of regulatory T cells on a simple tumor-immune interaction system

  2021cites this paper
• Possible Immunotherapeutic Strategies Based on Carcinogen-Dependent Subgroup Classification for Oral Cancer

  2021cites this paper
• Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors

  2021cites this paper
• Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms

  2021cites this paper
• A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy

  2021cites this paper
• Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma

  2021cites this paper
• Translational aspects of biologicals: monoclonal antibodies and antibody-drug conjugates as examples

  2021cites this paper
• Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity

  2021cites this paper
• Recruitment and Expansion of Tregs Cells in the Tumor Environment—How to Target Them?

  2021cites this paper
• The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors

  2021cites this paper
• Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis

  2020cites this paper
• ICOS+ Tregs: A Functional Subset of Tregs in Immune Diseases

  2020cites this paper
• Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy

  2020cites this paper
• Intra-hepatic Abscopal Effect Following Radioembolization of Hepatic Metastases

  2020cites this paper
• Checkpoint inhibition-induced sicca: a type II interferonopathy?

  2020cites this paper
• Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma

  2020cites this paper
• Learning from clinical trials of neoadjuvant checkpoint blockade

  2020cites this paper
• Human cancer germline antigen-specific cytotoxic T cell—what can we learn from patient

  2020cites this paper
• Sindbis Virus with Anti-OX40 Overcomes the Immunosuppressive Tumor Microenvironment of Low-Immunogenic Tumors

  2020cites this paper
• Immune Monitoring in Thoracic Malignancies

  2020cites this paper
• Combining radiation therapy and immunotherapy for lung cancers: a narrative review

  2020cites this paper
• DNA Encoded Library Technology-based discovery, lead optimization and prodrug strategy toward structurally-unique indoleamine 2,3-dioxygenase (IDO1) inhibitors.

  2020cites this paper
• Dual blockade of IL-6 and CTLA-4 regresses pancreatic tumors in a CD4+ T cell-dependent manner

  2020cites this paper
• Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials.

  2020cites this paper
• Immune classification of clear cell renal cell carcinoma

  2020cites this paper
• Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade

  2020cites this paper
• CTLA-4 (CD152): A versatile receptor for immune-based therapy.

  2019cites this paper
• Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies

  2019cites this paper
• Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner

  2019cites this paper
• Immunological and clinical implications of immune checkpoint blockade in human cancer

  2019cites this paper
• Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors.

  2019cites this paper
• Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy.

  2019cites this paper
• High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer

  2019cites this paper
• Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment

  2019cites this paper
• INHIBITION OF UROTHELIAL CARCINOMA BY TYPE I INTERFERON ACTIVATION OF THE INNATE AND ADAPTIVE IMMUNE RESPONSE

  2019cites this paper
• Development of immune checkpoint therapy for cancer

  2019cites this paper
• Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies.

  2019cites this paper
• Tackling molecular targets beyond PD-1/PD-L1: Novel approaches to boost patients' response to cancer immunotherapy.

  2019cites this paper
• Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy

  2019cites this paper
• Genetic variation in IRF4 expression modulates growth characteristics, tyrosinase expression and interferon‐gamma response in melanocytic cells

  2018cites this paper
• Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

  2018cites this paper
• Checkpoint Blockade Therapy

  2018cites this paper
• VOLARE: visual analysis of disease-associated microbiome-immune system interplay

  2018cites this paper
• T Lymphocyte-Based Cancer Immunotherapeutics.

  2018cites this paper